Abstract:Human studies consistently identify bioenergetic maladaptations in brains upon aging and neurodegenerative disorders of aging (NDAs), such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and Amyotrophic lateral sclerosis. Glucose is the major brain fuel and glucose hypometabolism has been observed in brain regions vulnerable to aging and NDAs. Many neurodegenerative susceptible regions are in the topological central hub of the brain connectome, linked by densely interconnected long-range axons. Axons, key components of the connectome, have high metabolic needs to support neurotransmission and other essential activities. Long-range axons are particularly vulnerable to injury, neurotoxin exposure, protein stress, lysosomal dysfunction, etc. Axonopathy is often an early sign of neurodegeneration. Recent studies ascribe axonal maintenance failures to local bioenergetic dysregulation. With this review, we aim to stimulate research in exploring metabolically oriented neuroprotection strategies to enhance or normalize bioenergetics in NDA models. Here we start by summarizing evidence from human patients and animal models to reveal the correlation between glucose hypometabolism and connectomic disintegration upon aging/NDAs. To encourage mechanistic investigations on how axonal bioenergetic dysregulation occurs during aging/NDAs, we first review the current literature on axonal bioenergetics in distinct axonal subdomains: axon initial segments, myelinated axonal segments, and axonal arbors harboring pre-synaptic boutons. In each subdomain, we focus on the organization, activity-dependent regulation of the bioenergetic system, and external glial support. Second, we review the mechanisms regulating axonal nicotinamide adenine dinucleotide (NAD+) homeostasis, an essential molecule for energy metabolism processes, including NAD+ biosynthetic, recycling, and consuming pathways. Third, we highlight the innate metabolic vulnerability of the brain connectome and discuss its perturbation during aging and NDAs. As axonal bioenergetic deficits are developing into NDAs, especially in asymptomatic phase, they are likely exaggerated further by impaired NAD+ homeostasis, the high energetic cost of neural network hyperactivity, and glial pathology. Future research in interrogating the causal relationship between metabolic vulnerability, axonopathy, amyloid/tau pathology, and cognitive decline will provide fundamental knowledge for developing therapeutic interventions.

Brain energetics and glucose transport in metabolic diseases: role in neurodegeneration

Sugar for the brain: the role of glucose in physiological and pathological brain function

Characteristic Metabolic Alterations Identified in Primary Neurons under High Glucose Exposure

Brain Metabolic Alterations in Alzheimer’s Disease

Glucose metabolic crosstalk and regulation in brain function and diseases

Mitochondria, energy, and metabolism in neuronal health and disease

Astrocytes as Key Regulators of Brain Energy Metabolism: New Therapeutic Perspectives

Brain Metabolism in Health and Neurodegeneration: The Interplay Among Neurons and Astrocytes

Brain metabolism in health, aging, and neurodegeneration

Fueling neurodegeneration: metabolic insights into microglia functions

Glucose Metabolic Dysfunction in Neurodegenerative Diseases—New Mechanistic Insights and the Potential of Hypoxia as a Prospective Therapy Targeting Metabolic Reprogramming

Potential mechanisms to modify impaired glucose metabolism in neurodegenerative disorders

Regulation of neuronal bioenergetics as a therapeutic strategy in neurodegenerative diseases

Weak neuronal glycolysis sustains cognition and organismal fitness

Astrocyte-Neuron Metabolic Crosstalk in Neurodegeneration: A Mitochondrial Perspective

Brain Energy Metabolism: Astrocytes in Neurodegenerative Diseases

Glial cell alterations in diabetes-induced neurodegeneration

Glycometabolic Reprogramming of Microglia in Neurodegenerative Diseases: Insights from Neuroinflammation

Axonal energy metabolism, and the effects in aging and neurodegenerative diseases

Brain Glucose Transporters: Role in Pathogenesis and Potential Targets for the Treatment of Alzheimer’s Disease

Brain development and bioenergetic changes